Refine/Revise Search
Asking Price: $250,000

Attractive Janitorial Business w/Recurring Revenue

Irvine, CA
Orange County

This janitorial business boasts a highly attractive book 50 homeowner’s associations (HOA) clients managed by 15 management companies.  The firm primarily provides day porter services as well as clubhouse, fitness center, and pool area cleaning.  Though the contracts have a 30 day termination clause, which tends to be industry standard, the mature relationships are deemed to be secure.  The company has an experienced supervisor and seasoned staff, in addition to a vehicle.  Staff work 7 days per week, with 3 team members dedicated to the largest HOA client.  Due to the company’s infrastructure being split between two separate business divisions, the seller only views this as an opportunity for an established and ongoing maintenance company that wishes to enter a new market segment (i.e. HOAs) and walk-into a coveted book of clients.  It is neither positioned, nor intended to be a sale as a stand-alone entity. It is recommended that a potential buyer look at the top line revenue, and some of the key COGs data, and determine what the underlying gross and net profit would be under their enterprise’s structure.  The seller will not meet or transact with a party that does not have an existing, ongoing complementary maintenance-related operation already in place.

Cash Flow Not Disclosed
Revenue $824,684
$ Owner Financing Available

Asking Price: $89,000

DiamondBrokerUSA Business Opportunity

Irvine, CA
Orange County

DiamondBrokerUSA — Exclusive Territory Licensing OpportunitiesOwn a Piece of the Luxury Jewelry MarketDiamondBrokerUSA is expanding nationwide and offering entrepreneurs the opportunity to own exclusive territorial rights with one of America’s most trusted jewelry brokerage brands.Our model blends the best of both worlds — the credibility of a luxury jewelry brand with the flexibility and profitability of an independent business. Licensees leverage our wholesale diamond network and marketing systems to build six-figure operations without the overhead of a traditional jewelry store.About the OpportunityWholesale Pricing Access — direct supplier relationships Flexible Model — home-based, retail showroom, or concierge serviceHigh-Margin Sales — luxury jewelry, custom pieces, and engagement ringsExclusive Territory Rights — protected market for your areaDiamondBrokerUSA provides a complete onboarding and training program covering:Diamond education and product sourcingBusiness setup and local market launchMarketing materials, website tools, and lead generation systemsOngoing mentorship and brand updates from corporate leadershipYou’ll be fully equipped to launch confidently and grow quickly with our experienced team behind you every step of the way.The U.S. jewelry industry generates more than $100 billion annually, with diamonds and engagement jewelry representing a core segment. DiamondBrokerUSA stands apart by combining wholesale access, luxury branding, and entrepreneurial independence.Traditional jewelers carry heavy inventory and high overhead; online retailers lack the local touch. DiamondBrokerUSA gives consumers the best of both — personal service at wholesale prices — and gives licensees an unmatched business model with minimal competition inside their territory.Initial License Fee to become a Broker: $9500Territory License fees range from $29,000-$299,000Includes: Training, onboarding, supplier access, marketing tools, and territorial exclusivityThis is not a franchise — it’s a licensing partnership that allows you to keep full control of your business and 100% of your profits.Ideal CandidateWe’re seeking driven individuals with a passion for entrepreneurship, sales, or luxury retail. Whether you have jewelry experience or are looking to build a new venture with national brand backing, this opportunity offers the tools and support to succeed.

Cash Flow Not Disclosed
Revenue Not Disclosed
$ Owner Financing Available

Asking Price: $35,000,000

Direct Lending & Real Estate Investments Services

Not Disclosed, CA
Not disclosed

Transworld Business Advisors of Orange presents:In business for 30 years, this 100% service-oriented company has been highly profitable and provides direct lending services and real estate investments.The business enjoys a stellar reputation and brand awareness in the industry, serving thousands of clients and investors over the decades.The business has been on a strong upward curve, with an average year over year revenue growth of over 35% since 2020. It has well-developed systems and processes in place to allow for future growth and expansion.Other investment highlights include:- A multi-source revenue business including loan origination, servicing, investments and trustee fees, thus controlling and benefiting from all aspects of the life cycle of the loan.- Long-term relationships between the business and, brokers and investors.- Great employees with experienced leaders in each department.- Serving clients in eight states (starting in 2020) with expected expansion onto additional states within the next two years.- On average, the company closes 60 to 100 loans each month, with most months exceeding 75.- As one of the oldest private money lenders in California, the pipeline of the business is largely generated by broker referrals.*** $5,000,000 in cash or trust deeds included in the sale. ***The owner is retiring after 20 years in the business and will help the new owners with transition.Agent: Nassim Bayat DRE# 01958611

Cash Flow $7,482,883
Revenue $16,279,065

Asking Price: $20,000,000

Patented Universal Tumor-Targeting Drug Delivery

Irvine, CA
Orange County

Patented Universal Tumor-Targeting Drug Delivery Platform Co.This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company’s ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company’s ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to 'universally' target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers.The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin.The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations.As the Company’s platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI.The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); followed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company’s valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approximately 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support.NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners.

Cash Flow Not Disclosed
Revenue Not Disclosed
$ Owner Financing Available

loading...
TOP â–²
Add Businesses and/or Franchises
To Basket For Free Information

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information for more details.